Short bowel syndrome (SBS) is the main cause of chronic intestinal failure (IF), defined as ‘the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth’. SBS is a rare disease requiring a multidisciplinary approach in specialized IF units. The aim of this review was to discuss the current pharmacological management of SBS-associated IF, since emerging treatments are currently modifying the natural evolution of these patients. Enterohormone therapy has become the first-choice treatment and may decrease the need for parenteral support and improve patients' quality of life.

短肠综合征 (SBS) 是慢性肠衰竭 (IF) 的主要原因，其定义为“肠道功能降低到吸收大量营养素和/或水和电解质所需的最低限度以下，因此需要静脉补充以维持健康和/或成长”。SBS 是一种罕见疾病，需要在专门的 IF 单位采取多学科方法。本综述的目的是讨论目前 SBS 相关 IF 的药理学管理，因为新兴的治疗方法目前正在改变这些患者的自然进化。肠激素治疗已成为首选治​​疗方法，可能会减少对肠外支持的需求并提高患者的生活质量。